USPTO serial 86790734
GLYCODX
Reviewed by CopyMark Law Group
Reg. 5583190Status 710
- Filing date
- Status date
- Registration date
- Oct 16, 2018
- Examiner
- HACK, ANDREA R
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with GLYCODX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Taipei City 115, TW
Taipei City 115, TW
Taipei City, TW
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ran He
10190 Harwin Dr. Ste BHouston, TX 77036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | amino acids for medical purposes; biological preparations for the treatment of immune system related diseases, cancer and infectious diseases for medical purposes; blood for medical purposes; blood plasma; capsules sold empty for pharmaceuticals; chemical reagents for medical purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemico-pharmaceutical preparations for the treatment of immune system related diseases, cancer and infectious diseases for medical purposes; detergents for medical purposes; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; drugs for medical purpose, namely, pharmaceutical preparations for the treatment of immune system related diseases, cancer and infectious diseases; pharmaceutical preparations for treatment of immune system related diseases, cancer and infectious diseases; reagent paper for medical purposes; medicated serums for treatment of immune system related diseases, cancer and infectious diseases; sugar for medical purposes; vaccines; Anti-cancer preparations; Biological preparations for the treatment of cancer; Diagnostic agents, preparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers and reagents for use in disease testing; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic radiopharmaceutical preparations; Diagnostic reagents for medical use; Diagnostic reagents and contrast media for medical use; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; In-vivo diagnostic agent used for detection and monitoring of angiogenesis and antiangiogenic therapy; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing body fluids; Medical diagnostic reagents for the analysis of body fluids; Medicinal preparations for the treatment of infectious diseases and for using in oncology; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Reagents for medical use; Vaccine adjuvants; Vaccine preparations; Vaccine stabilizers | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 2, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Mar 27, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 27, 2024 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Mar 27, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 27, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 27, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 16, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 16, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 31, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 31, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 22, 2018 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jun 22, 2018 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 21, 2018 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Jun 21, 2018 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jun 21, 2018 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Jun 21, 2018 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jun 12, 2018 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Jun 4, 2018 | PILM | PETITION INQUIRY LETTER ISSUED | — |
| Jun 1, 2018 | APET | ASSIGNED TO PETITION STAFF | — |
| May 1, 2018 | PAPER RECEIVED | — | |
| Apr 27, 2018 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 28, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 26, 2018 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 26, 2018 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 26, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 20, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 4, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 4, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 4, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 8, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 8, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 8, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 25, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 30, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 30, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 10, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 26, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 21, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 14, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jul 8, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 21, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 20, 2015 | NWAP | NEW APPLICATION ENTERED | — |